Back

Soluble urokinase plasminogen activator receptor predicts survival and hospitalization for heart failure in elective cardiac surgery

26 August 2022 (08:00 - 19:30)
Organised by:
Congress Presentation Part of: The broad spectrum of cardiovascular surgery Coronary Arteries ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Doctor Lorenz Koller

Medical University of Vienna, Vienna (Austria)

6 More presentations in this session

Presentation thumbnail
Can carotid angioplasty stenting be better than endarterectomy or best medical treatment for patients with carotid stenosis?
Doctor R. Fernandes (Coimbra, PT)
Abstract Slides
Presentation thumbnail
Are severe mitral annular calcification still a contraindication to open surgery?
Doctor F. Petrini (Florence, IT)
Abstract Slides
Presentation thumbnail
Circulating miRNA-770-5p and miRNA-30d-5p as potential biomarkers in vasoplegic syndrome after on-pump coronary artery bypass surgery - PREVENT trial
Doctor B. Meneghini (Sao Paulo, BR)
Abstract Slides
Presentation thumbnail
Redo cardiac surgery in the era of percutaneous solutions: pattern of presentation and outcomes in a single tertiary care center
Doctor A. Montella (Naples, IT)
Abstract Slides
Presentation thumbnail
Thrombocytopenia following implantation of different types of bioprosthetic aortic valves in severe aortic valve stenosis replacement
Associate Professor K. LAMPROPOULOS (Athens, GR)
Abstract Slides

Access the full session

Session thumbnail
The broad spectrum of cardiovascular surgery

The Event

Event poster

ESC Congress 2022

26 August - 29 August 2022
You may be interested in
thumbnail
Congress Presentation
Anomalous left main coronary artery arising from the right coronary sinus presenting with ST elevation and non ST elevation myocardial infarction
thumbnail
Congress Presentation
Surgical correction of anomalous origin of the coronary artery: a scoping review on clinical outcomes, techniques, and knowledge gaps
thumbnail
Webinar
Chronic coronary syndrome post-myocardial infarction: disease progression and comorbidities

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources